Amyris Inc Stock Research

Market Summary

USD0.82+0.07

Delayedas of 31 May 2023, 02:08 pm

9.31%

AMRS Stock Price

AMRS RSI Chart

AMRS Valuation

Market Cap

277.1M

Price/Earnings (Trailing)

-0.52

Price/Sales (Trailing)

1.03

EV/EBITDA

-0.44

Price/Free Cashflow

-0.6

AMRS Price/Sales (Trailing)

AMRS Profitability

EBT Margin

-135.65%

Return on Equity

79.72%

Return on Assets

-45.2%

Free Cashflow Yield

-167.28%

AMRS Fundamentals

AMRS Revenue

Revenue (TTM)

268.2M

Revenue Y/Y

-2.82%

Revenue Q/Q

-26.01%

AMRS Earnings

Earnings (TTM)

-528.5M

Earnings Y/Y

-495.82%

Earnings Q/Q

7.19%

Price Action

52 Week Range

0.554.86

(Low)(High)

Last 7 days

1.0%

Last 30 days

-8.0%

Last 90 days

-36.8%

Trailing 12 Months

-71.8%

AMRS Financial Health

Current Ratio

0.88

AMRS Investor Care

Shares Dilution (1Y)

19.30%

Diluted EPS (TTM)

-1.92

Peers (Alternatives to Amyris)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
LYB	28.2B	47.5B	-8.34%	-19.49%	9.28	0.59	-5.39%	-48.13%
PPG	26.8B	17.7B	-4.21%	4.38%	24.98	1.52	2.87%	18.13%
IFF	19.9B	12.2B	-19.34%	-40.77%	-10.7	1.63	-1.42%	-768.10%
WLK	15.1B	15.1B	-4.69%	-17.30%	6.74	0.96	12.00%	-25.52%
RPM	10.3B	7.2B	-2.77%	-11.41%	19.52	1.42	11.69%	17.31%
MID-CAP
OLN	6.4B	8.8B	-11.23%	-25.87%	5.85	0.73	-7.34%	-24.77%
AXTA	5.3B	5.0B	-5.10%	7.77%	26.11	1.1	10.33%	-27.28%
NEU	3.8B	2.8B	-1.18%	17.82%	11.96	1.36	14.40%	76.05%
SXT	3.2B	1.5B	-2.01%	-16.73%	22.49	2.2	5.41%	10.73%
GCP	2.4B	-	1.27%	44.25%	215.39	2.37	-	-
SMALL-CAP
WLKP	809.2M	1.5B	-4.59%	-19.92%	10.8	0.56	17.52%	-46.24%
FF	393.9M	427.9M	20.00%	23.63%	8.09	0.92	27.12%	91.20%
AMRS	277.1M	268.2M	-8.05%	-71.84%	-0.52	1.03	20.46%	-95.04%

Financials for Amyris

Income Statement (Last 12 Months)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1
Revenue	-0.6%	268,221,000	269,847,000	258,821,000	235,558,000	222,667,000
S&GA Expenses	-2.2%	482,583,000	493,629,000	453,126,000	399,052,000	326,805,000
R&D Expenses	0.4%	110,622,000	110,215,000	105,958,000	101,002,000	97,315,000
Costs and Expenses	7.1%	898,173,000	838,830,000	803,838,000	719,242,000	617,799,000
EBITDA	-71.1%	-313,100,000	-182,997,000	-62,647,000	-	-
EBITDA Margin	-55.7%	-1.21	-0.78	-0.28	-	-
Earnings Before Taxes	-17.1%	-630,997,000	-538,625,000	-351,102,000	-218,064,000	-92,187,000
EBT Margin	-46.5%	-1.36	-0.93	-0.44	-	-
Interest Expenses	31.2%	32,453,000	24,733,000	27,604,000	25,636,000	25,055,000
Net Income	-55.0%	-528,510,000	-340,868,000	-212,417,000	-87,023,000	-
Net Income Margin	-46.0%	-1.32	-0.90	-0.39	-	-
Free Cahsflow	-12.6%	-575,187,000	-511,021,000	-442,426,000	-	-

Balance Sheet					(In Millions)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1
Assets	-17.6%	680	825	754	789	898
Current Assets	-20.5%	244	306	272	310	471
Cash Equivalents	-72.9%	17.00	64.00	18.00	100	288
Inventory	-2.6%	109	112	129	99.00	82.00
Net PPE	4.1%	190	182	170	151	125
Goodwill	-64.6%	50.00	143	127	134	1.00
Liabilities	2.7%	1,328	1,293	1,159	1,033	1,024
Current Liabilities	21.6%	471	387	309	187	266
LT Debt, Current	2.7%	2.00	2.00	2.00	1.00	1.00
LT Debt, Non Current	0.1%	676	675	674	673	672
Shareholder's Equity	-35.9%	-664	-488	-	-	-
Retained Earnings	-6.0%	-3,073	-2,900	-2,730	-2,568	-2,458
Additional Paid-In Capital	0.4%	2,466	2,456	2,384	2,357	-
Accumulated Depreciation	2.3%	99.00	96.00	95.00	-	-
Shares Outstanding	1.0%	369	365	325	321	309
Minority Interest	24.4%	-9.76	-12.91	-13.10	-6.60	-3.52

Cashflow (Last 12 Months)					(In Millions)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1
Cashflow From Operations	11.9%	-463	-525	-575	-511	-442
Share Based Compensation	-11.9%	43.00	49.00	48.00	45.00	41.00
Cashflow From Investing	34.3%	-81.24	-123	-142	-147	-108
Cashflow From Financing	16.3%	269	231	626	550	698

Risks for AMRS

What is the probability of a big loss on AMRS?

100%

Probability that Amyris stock will be more than 20% underwater in next one year

94.2%

Probability that Amyris stock will be more than 30% underwater in next one year.

93.8%

Probability that Amyris stock will be more than 40% underwater in next one year.

*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does AMRS drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Amyris was unfortunately bought at previous high price.

Drawdowns

Returns for AMRS

Cumulative Returns on AMRS

-33.6%

10-Year Cumulative Returns

-29.4%

7-Year Cumulative Returns

-32%

5-Year Cumulative Returns

-41.4%

3-Year Cumulative Returns

What are the long-term rolling returns for AMRS?

FIve years rolling returns for Amyris.

Annualized Returns

Which funds bought or sold AMRS recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
2023-05-26	ProShare Advisors LLC	reduced	-7.07	-6,857	32,568	-%
2023-05-26	SHEETS SMITH WEALTH MANAGEMENT	sold off	-100	-82,836	-	-%
2023-05-22	AMERIPRISE FINANCIAL INC	reduced	-8.44	-6,741	27,259	-%
2023-05-22	Arete Wealth Advisors, LLC	reduced	-7.92	-19,301,800	16,000	-%
2023-05-18	NEW YORK STATE COMMON RETIREMENT FUND	reduced	-73.96	-142,000	43,000	-%
2023-05-18	JPMORGAN CHASE & CO	reduced	-22.46	-1,004,000	2,226,000	-%
2023-05-17	Advisory Services Network, LLC	unchanged	-	-21.00	170	-%
2023-05-17	B. Riley Wealth Advisors, Inc.	unchanged	-	-12,631	101,048	-%
2023-05-16	CVI Holdings, LLC	sold off	-100	-27,791,800	-	-%
2023-05-16	IMA Wealth, Inc.	unchanged	-	-42.00	340	-%

Latest Funds Activity

Are funds buying AMRS calls or puts?

Calls

Puts

Are funds bullish or bearish(Calls - Puts)?

Net Call Options

No. of funds that own AMRS

No. of Funds

Amyris News

Schedule 13G FIlings of Amyris

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
May 24, 2023	foris ventures, llc	29.9%	120,177,411	SC 13D/A
Mar 17, 2023	foris ventures, llc	30.1%	119,877,165	SC 13D/A
Feb 14, 2023	cvi investments, inc.	4.9%	18,163,117	SC 13G/A
Feb 09, 2023	vanguard group inc	5.84%	21,211,189	SC 13G/A
Feb 07, 2023	farallon capital partners, l.p.	0.0%	64,221	SC 13G/A
Jan 09, 2023	foris ventures, llc	33.5%	119,710,362	SC 13D/A
Jan 04, 2023	cvi investments, inc.	5.5%	2e+07	SC 13G
Dec 16, 2022	dsm international b.v.	-	0	SC 13D/A
Sep 15, 2022	foris ventures, llc	28.0%	96,051,761	SC 13D/A
Sep 08, 2022	foris ventures, llc	27.5%	93,989,044	SC 13D/A

AMRS Fair Value

Show Fair-Value

Recent SEC filings of Amyris

View All Filings

Date Filed	Form Type	Document
May 26, 2023	8-K	Current Report
May 24, 2023	SC 13D/A	13D - Major Acquisition
May 10, 2023	10-Q	Quarterly Report
May 09, 2023	8-K	Current Report
Apr 24, 2023	EFFECT	EFFECT
Apr 24, 2023	EFFECT	EFFECT
Apr 24, 2023	8-K	Current Report
Apr 21, 2023	4	Insider Trading
Apr 21, 2023	4	Insider Trading
Apr 21, 2023	4	Insider Trading

Latest Insider Trading transactions for AMRS

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
2023-04-19	Panchadsaram Ryan	acquired	-	-	9,667	-
2023-04-19	MCCANN JAMES F	acquired	-	-	13,437	-
2023-04-19	Qi Lisa	acquired	-	-	10,537	-
2023-04-19	DOERR L JOHN	acquired	-	-	11,600	-
2023-04-05	ALVAREZ EDUARDO	sold	-284,305	1.2288	-231,368	chief operating officer
2023-04-04	ALVAREZ EDUARDO	acquired	-	-	492,000	chief operating officer
2023-01-20	Qi Lisa	acquired	-	-	7,532	-
2023-01-20	Panchadsaram Ryan	acquired	-	-	7,947	-
2023-01-20	MCCANN JAMES F	acquired	-	-	9,605	-
2023-01-20	DOERR L JOHN	acquired	-	-	8,292	-

About Amyris

John G. Melo

www.amyris.com

980

Amyris, Inc., a synthetic biotechnology company, operates in the clean health and beauty, and flavors and fragrance markets in Europe, North America, Asia, and South America. The company manufactures and sells clean beauty, personal care, and health and wellness consumer products, as well as ingredients to the flavor and fragrance, nutrition, food and beverage, and clean beauty and personal care end markets. It offers its products under the Biossance, Pipette, Purecane, Terasana, Costa Brazil, OLIKA, Rose Inc., and JVN brand names. The company has a collaboration agreement with the Infectious Disease Research Institute for the development of a COVID-19 vaccine. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was incorporated in 2003 and is headquartered in Emeryville, California.

AMRS Income Statement

2023-03-31

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Revenue:
Revenue	$ 56,083	$ 57,709
Cost and operating expenses:
Cost of products sold	51,081	48,995
Research and development	26,765	26,358
Sales, general and administrative	95,870	106,916
Change in fair value of acquisition-related contingent consideration	(28,503)	0
Restructuring	1,013	0
Impairment	95,386	0
Total cost and operating expenses	241,612	182,269
Loss from operations	(185,529)	(124,560)
Other income (expense):
Interest expense	(12,983)	(5,263)
Gain from change in fair value of derivative instruments	1,263	1,815
(Loss) gain from change in fair value of debt	(4,854)	20,796
Other expense, net	(533)	(3,052)
Total other (expense) income, net	(17,107)	14,296
Loss before income taxes and loss from investment in affiliate	(202,636)	(110,264)
Benefit from income taxes	860	820
Loss from investment in affiliate	0	(789)
Net loss	(201,776)	(110,233)
Loss attributable to noncontrolling interest	8,434	2,928
Net loss attributable to Amyris, Inc. common stockholders	$ (193,342)	$ (107,305)
Earnings Per Share [Abstract]
Net loss per share attributable to common stockholders, basic (in dollars per share)	$ (0.53)	$ (0.34)
Weighted-average shares of common stock outstanding used in computing net loss per share of common stock, basic (in shares)	365,603,738	312,896,452
Net loss per share attributable to common stockholders, diluted (in dollars per share)	$ (0.53)	$ (0.37)
Weighted-average shares of common stock outstanding used in computing net loss per share of common stock, diluted (in shares)	365,603,738	323,711,682
Renewable Products
Revenue:
Revenue	$ 40,224	$ 43,465
Licenses and Royalties
Revenue:
Revenue	9,482	9,313
Collaborations, Grants and Other
Revenue:
Revenue	$ 6,377	$ 4,931

AMRS Balance Sheet

2023-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 11,245	$ 64,437
Restricted cash	71	71
Accounts receivable, net of allowance of $997 and $995	36,842	45,775
Accounts receivable - related party, net of allowance of $0 and $0	10,836	6,608
Contract assets	3,872	806
Contract assets - related party	33,679	36,638
Inventories	109,021	111,880
Prepaid expenses and other current assets	38,095	40,146
Total current assets	243,661	306,361
Property, plant and equipment, net	189,645	182,224
Restricted cash, noncurrent	6,135	6,090
Recoverable taxes from Brazilian government entities	30,189	29,472
Right-of-use assets under financing leases, net	147	152
Right-of-use assets under operating leases, net	100,721	97,216
Goodwill	50,456	142,575
Intangible assets, net	45,063	46,938
Other assets	13,662	13,904
Total assets	679,679	824,932
Current liabilities:
Accounts payable	200,067	190,486
Accrued and other current liabilities	81,068	73,565
Financing lease liabilities	14	13
Operating lease liabilities	2,484	2,255
Contract liabilities	33	26
Debt, current portion	1,968	1,916
Related party debt, current portion	185,160	118,886
Total current liabilities	470,794	387,147
Long-term debt, net of current portion	675,855	674,891
Related party debt, net of current portion	77,962	97,350
Financing lease liabilities, net of current portion	44	48
Operating lease liabilities, net of current portion	90,986	86,195
Derivative liabilities	4,140	5,403
Acquisition-related contingent consideration	2,241	34,555
Other noncurrent liabilities	5,725	7,053
Total liabilities	1,327,747	1,292,642
Commitments and contingencies
Mezzanine equity:
Contingently redeemable common stock	0	5,000
Contingently redeemable noncontrolling interest	26,058	28,892
Stockholders’ (deficit) equity:
Common stock - $0.0001 par value, 550,000,000 shares authorized as of March 31, 2023 and December 31, 2022; 368,524,240 and 364,745,266 shares issued and outstanding as of March 31, 2023 and December 31, 2022	37	36
Additional paid-in capital	2,465,802	2,455,567
Accumulated other comprehensive loss	(56,682)	(64,114)
Accumulated deficit	(3,073,520)	(2,880,178)
Total Amyris, Inc. stockholders’ (deficit) equity	(664,363)	(488,689)
Noncontrolling interest	(9,763)	(12,913)
Total stockholders' (deficit) equity	(674,126)	(501,602)
Total liabilities, mezzanine equity and stockholders' (deficit) equity	$ 679,679	$ 824,932